ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/neurological
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Head & neck and Neurological / Neurological
21
trial(s) found.
NCT06926075
Advanced
Phase 1
Not yet recruiting
An Adaptive Phase I/II Study of Kesonotide, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours (
ADVICE
)
Breast cancer
Glioblastoma
Lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
NCT06326411
Advanced
Phase 1
Recruiting
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue
NST-628
Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
pan-RAF/MEK glue
Glioma
Melanoma
NOT Melanoma
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06208657
Advanced
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (
OPTIMISE
)
Irinotecan
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Temozolomide
alkylating agent
cancer therapy
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT06157541
Advanced
Phase 1 / Phase 2
Recruiting
Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme (
TCaP
)
anti-PD-1 monoclonal antibody
Astrocytoma
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
NA
NA
NCT05577416
Advanced
Phase 1
Recruiting
A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (
AB-218-IIT-201
)
IDH1 R132 inhibitor
Low-grade glioma
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
NCT05503797
Advanced
Phase 2
Recruiting
A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations (
F8394-201
)
RAF dimer inhibitor
Cancer
Central nervous system cancer
Melanoma
NOT Colorectal adenocarcinoma
NOT Melanoma
NOT Non-small cell lung cancer
NOT Pancreatic adenocarcinoma
NOT Thyroid cancer
Solid tumour
Thyroid cancer
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT05450744
Advanced
Phase 1
Recruiting
A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma (
IPAX-2
)
131I-IPA
131I-TLX-101
cancer therapy
cancer therapy,LAT1-targeting
cancer therapy,LAT2-targeting
radioiodine conjugate
radioiodine therapy
radioligand,LAT1/LAT2-targeting
radiopharmaceutics
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre
NCT05286801
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (
NCI-2022-01992
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
Atypical teratoid rhabdoid tumour
Carcinoma
Chordoma
Epithelioid sarcoma
Rhabdoid tumour
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT04870944
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma (
PEPN2111
)
curaxin,FACT complex-targeting
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
H3K27M-mutant glioma
Lymphoma
Osteosarcoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
NCT04221035
Advanced
Phase 3
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (
HR-NBL2
)
Busulfan
Carboplatin
Cisplatin
Cyclophosphamide
Dacarbazine
Dinutuximab
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Melphalan
Radiotherapy
Temozolomide
Thiotepa
Vincristine
alkylating agent
anthracycline
anti-GD2 monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT03970447
Advanced
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VAL-083
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
NSW
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12623001126606
Advanced
Phase 1 / Phase 2
Recruiting
Phase I/II clinical trial evaluating the safety and efficacy of allogeneic cytomegalovirus-specific T cells in combination with pembrolizumab for recurrent and newly diagnosed glioblastoma multiforme (
TCaP
)
anti-PD-1 monoclonal antibody
Astrocytoma
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622001514796
Advanced
Not Applicable
Recruiting
KARPOS
- A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme
Bevacizumab
CAR-T-cell therapy
CAR-T-cell therapy,GD2-targeting
Cyclophosphamide
Fludarabine
GD2-iCAR-PBT
Ifosfamide
alkylating agent
anti-VEGF monoclonal antibody
antimetabolite
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,GD2-targeting
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cell therapy
cytotoxic chemotherapy
immuno-oncology therapy,VEGF-targeting
Glioblastoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12622001201763
Advanced
Phase 2
Recruiting
Efficacy of Treatment Targeting the Renin-Angiotensin System in Glioblastoma (
TRAS-GB
) Trial
COX2 inhibitor
Celecoxib
Metformin
Propranolol
Radiotherapy
Temozolomide
alkylating agent
antihypertensives
beta-adrenergic blocker
biguanide antihyperglycaemic agent
cancer therapy
cancer therapy,COX2-targeting
cytotoxic chemotherapy
Glioblastoma
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12621001172897
Advanced
Phase 1
Recruiting
A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors (PART B). (
ACT001-AU-001
)
NFKB inhibitor
Glioblastoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05500508
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer (
AMXT1501-102
)
polyamine transport inhibitor
Breast cancer
Cancer
Central nervous system cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
H3K27M-mutant glioma
Head and neck cancer
Malignant glioma
Melanoma
Mesothelioma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Papillary thyroid cancer
Pleural mesothelioma
Solid tumour
NSW
2145 - Westmead - The Children's Hospital at Westmead
NCT05187624
Advanced
Phase 1
Not recruiting
An Open-label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III (
BP42573
)
bispecific T-cell engager,EGFRvIII-targeting
Glioblastoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT03722342
Advanced
Phase 1
Unknown
A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma (
PMC-TTAC-0001-04
)
anti-PD-1 monoclonal antibody
anti-VEGFR2 monoclonal antibody
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12619000640101
Advanced
Phase 2
Status unknown
A Phase 2, open label study of orally administered PAX-1 monotherapy in patients with recurrent glioblastoma.
sodium arsenite
Glioblastoma
ACT
2605 - Garran - The Canberra Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (16)
Not yet recruiting (1)
Terminated (1)
Not recruiting (1)
Unknown (1)
Status unknown (1)
Recruitment Country and State
VIC (16)
NSW (11)
QLD (9)
SA (8)
WA (5)
NZ (2)
TAS (1)
ACT (1)
Phase
Phase 1 (7)
Phase 1 / Phase 2 (6)
Phase 2 (5)
Phase 2 / Phase 3 (1)
Phase 3 (1)
Trial Type
Advanced (21)
Paediatric (1)
Cancer Therapy Class
PD-1/PD-L1
29%
PD-1
24%
PI3K-delta
14%
PI3K
14%
PI3Kalpha
14%
mTOR
14%
mTORC1
14%
mTORC2
14%
BRAF
10%
RAF
10%
GD2
10%
CRAF
5%
MEK
5%
pan-RAF
5%
IDH1
5%
IDH1 R132
5%
LAT1
5%
LAT2
5%
PD-L1
5%
TIGIT
5%
FACT complex
5%
FGFR
5%
FGFR1
5%
FGFR1/2/3
5%
FGFR2
5%
FGFR3
5%
FGFR4
5%
KIT
5%
PDGFR
5%
RET
5%
VEGFR
5%
MET
5%
CTLA4
5%
PARP
5%
XPO1
5%
VEGF
5%
COX2
5%
NFKB
5%
polyamine transport
5%
EGFRvIII
5%
VEGFR2
5%
Facility
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
2031 - Randwick - Sydney Children's Hospital (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
5042 - Bedford Park - Flinders Medical Centre (4)
2145 - Westmead - The Children's Hospital at Westmead (3)
3052 - Parkville - Royal Children's Hospital Melbourne (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (2)
2305 - New Lambton Heights - John Hunter Children's Hospital (2)
4101 - South Brisbane - Queensland Children's Hospital (2)
6009 - Perth - Perth Children's Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3168 - Clayton - Monash Medical Centre (2)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
3168 - Clayton - Monash Children's Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
NA
3004 - Melbourne, Southbank - Alfred Health (1)
4215 - Southport - Gold Coast University Hospital (1)
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
2170 - Liverpool - Liverpool Hospital (1)
3066 - Epping - Northern Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
2605 - Garran - The Canberra Hospital (1)
Cancer Type
Cancer
Neurological cancer
Solid tumour
Central nervous system cancer
Glioma
Malignant glioma
High-grade glioma
Glioblastoma
Lung cancer
Respiratory tract cancer
Thoracic cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Melanoma
Non-small cell lung cancer
Endocrine gland cancer
Thyroid cancer
Breast cancer
Gynaecological cancer
Ovarian cancer
Pancreatic cancer
Pancreatobiliary cancer
Urogenital cancer
Astrocytoma
Low-grade glioma
Bone cancer
Sarcoma
H3K27M-mutant glioma
Colorectal cancer
Gastric cancer
Gastroesophageal cancer
Lower gastrointestinal cancer
Oesophageal cancer
Male genital cancers
Prostate cancer
Skin cancer
Atypical teratoid rhabdoid tumour
Carcinoma
Central nervous system primitive neuroectodermal tumour
Chordoma
Epithelioid sarcoma
Ewing family of tumours
Rhabdoid tumour
Soft tissue sarcoma
Diffuse intrinsic pontine glioma
Haematological malignancy
Lymphoma
Osteosarcoma
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
Colon adenocarcinoma
Colorectal adenocarcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Kidney cancer
MET:alteration
MET:fusion
Anaplastic astrocytoma
Cervical cancer
Differentiated thyroid carcinoma
Endometrial cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Mesothelioma
Papillary thyroid cancer
Pleural mesothelioma
Viral-related cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy